Hemin

Identification

Summary

Hemin is an iron-containing porphyrin injection used for the relief of recurrent attacks of acute intermittent porphyria (AIP) associated with the menstrual cycle when carbohydrate therapy is not effective.

Brand Names
Panhematin
Generic Name
Hemin
DrugBank Accession Number
DB03404
Background

Hemin (trade name Panhematin) is an iron-containing porphyrin. More specifically, it is protoporphyrin IX containing a ferric iron ion (heme B) with a chloride ligand.

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Blood factors
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • chloro(protoporphyrinato)iron(III)
  • Hämin
  • Hemina
  • hémine
  • protohemin

Pharmacology

Indication

Used in the management of porphyria attacks, particularly in acute intermittent porphyria.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Management ofAcute porphyria••••••••••••
Management ofHereditary coproporphyria••••••••••••
Management ofPorphyria variegata••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabHemin may increase the anticoagulant activities of Abciximab.
AcenocoumarolHemin may increase the anticoagulant activities of Acenocoumarol.
AlteplaseHemin may increase the anticoagulant activities of Alteplase.
AncrodHemin may increase the anticoagulant activities of Ancrod.
AnistreplaseHemin may increase the anticoagulant activities of Anistreplase.
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
PanhematinPowder, for solution7 mg/1mLIntravenousRECORDATI RARE DISEASES, INC.1983-07-20Not applicableUS flag
PanhematinInjection, powder, lyophilized, for solution7 mg/1mLIntravenousRecordati Rare Diseases Inc1983-07-202020-01-24US flag
PanhematinPowder, for solution268 mg / vialIntravenousRecordati Rare Diseases Canada Inc2018-12-05Not applicableCanada flag
PanhematinInjection, powder, lyophilized, for solution7 mg/1mLIntravenousLundbeck Inc.1983-07-202013-07-18US flag

Categories

ATC Codes
B06AB01 — Hemin
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
743LRP9S7N
CAS number
16009-13-5

References

General References
Not Available
Human Metabolome Database
HMDB0000887
KEGG Compound
C06767
PubChem Substance
46504761
ChemSpider
401223
RxNav
5175
ChEBI
50385
RxList
RxList Drug Page
Wikipedia
Hemin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedPreventionGraft Failure / Ischemia Reperfusion Injury1
2CompletedTreatmentAcute Porphyria1
2CompletedTreatmentDiabetes Mellitus / Gastroparesis1
2CompletedTreatmentMyocardial Ischemia1
2CompletedTreatmentPost ERCP Acute Pancreatitis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, lyophilized, for solutionParenteral313 mg
Injection, solution, concentrateIntravenous25 MG/ML
Injection, solution, concentrateIntravenous
Solution, concentrateIntravenous25 mg
Injection, powder, lyophilized, for solutionIntravenous7 mg/1mL
Powder, for solutionIntravenous268 mg / vial
Powder, for solutionIntravenous7 mg/1mL
PowderIntravenous350 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Drug created at June 13, 2005 13:24 / Updated at April 30, 2021 13:05